Nature Aging Review Synthesizes Molecular Mechanisms of Dietary Restriction and Candidate Mimetics

A collaborative review published in Nature Aging consolidates three decades of mammalian research on dietary restriction, detailing key cellular pathways and validating candidate pharmacological mimetics to improve healthspan.

In March 2026, researchers published a comprehensive review in Nature Aging outlining the cellular and molecular mechanisms of dietary restriction (DR) in mammalian longevity.

The review, co-authored by scientists from institutions including the University of Oslo, Calico Life Sciences, and the National Institute on Aging, maps out several critical cellular cascades activated by DR, including autophagy, sirtuins, mTORC1, AMPK, FGF21, and NAD+ metabolism.

The authors also examine potential physiological trade-offs of prolonged DR, such as impaired wound healing and increased vulnerability to infections.

Dietary restriction has served as the foundational benchmark for experimental life extension, but its strict implementation remains challenging for humans.

Characterizing the precise molecular pathways of DR allows the longevity field to focus on 'dietary restriction mimetics'—molecules that can chemically trigger the same downstream healthspan-extending cascades without requiring caloric deprivation.

The review highlights the critical role of metabolic adaptations, such as fasting-induced ketogenesis and changes in core body temperature, as key targets for therapeutic design.

This high-profile review solidifies the biological consensus for target pathways utilized by biotech companies developing longevity therapeutics.

Clinical-stage and preclinical programs targeting autophagy, mTORC1, and NAD+ replenishment receive further validation of their core mechanisms of action from the consolidated mammalian evidence.

The highlighted safety risks, including immune suppression and slow wound repair, emphasize the need for tissue-selective or transient therapeutic regimens rather than systemic, continuous pathway inhibition.

Future translational developments are expected to focus on characterizing human biological responses to specific macronutrient restriction paradigms and validating the safety profile of candidate mimetics in clinical trials.